{"id":"yisaipu","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug functions as a TNF inhibitor by acting as a soluble TNF receptor that captures circulating TNF-α and TNF-β, preventing their interaction with cell surface TNF receptors. This mechanism suppresses the inflammatory cascade driven by TNF, making it useful in TNF-mediated inflammatory and autoimmune conditions. It is structurally similar to etanercept, another TNF receptor fusion protein.","oneSentence":"Yisaipu is a recombinant human TNF receptor II-IgG fusion protein that binds and neutralizes tumor necrosis factor (TNF) to reduce inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:45.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT02364479","phase":"PHASE4","title":"Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-02-10","conditions":"Spondyloarthritis","enrollment":150},{"nctId":"NCT02960035","phase":"PHASE4","title":"A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-04","conditions":"Spondyloarthropathy","enrollment":96},{"nctId":"NCT03411798","phase":"PHASE4","title":"Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-12-15","conditions":"Ankylosing Spondylitis","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["methotrexate(MTX)","sulfasalazine(SSZ)","hydroxychloroquine(HCQ)"],"phase":"marketed","status":"active","brandName":"Yisaipu®","genericName":"Yisaipu®","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Yisaipu is a recombinant human TNF receptor II-IgG fusion protein that binds and neutralizes tumor necrosis factor (TNF) to reduce inflammatory responses. Used for Rheumatoid arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}